ライフサイエンスコーパス: gp120

1 due 43 of CD4 (a phenylalanine) engages with gp120.

2 to some bNAbs targeting different regions of gp120.

3 y appeared to target the CD4 binding site on gp120.

4 HVEM binding domain of HSV-1 gD fused to HIV gp120.

5 negatively-charged complex-type N-glycans on gp120.

6 while no changes are observed with monomeric gp120.

7 he V1 and V2 hyper-variable domains of HIV-1 gp120.

8 d the N terminus with N276 and V5 glycans of gp120.

9 D4 binding site of the envelope glycoprotein gp120.

10 ot induced upon immunization of rabbits with gp120.

11 ting the V1/V2 loops of the envelope protein gp120.

12 odies to the Env trimer but not to monomeric gp120.

13 the native Env trimer compared to monomeric gp120.

14 tibodies in the Env trimer but not monomeric gp120.

15 ct on CD4 binding than does layer 3 in HIV-1 gp120.

16 ative spike, including the bridging sheet on gp120.

17 etate and paclitaxel or HIV envelope protein gp120.

18 fection by blocking CCR5 engagement with HIV gp120.

19 hen transfected with a plasmid encoding HIV1-gp120.

20 ellular matrix proteins that copurified with gp120.

21 utralizing anti-V3 loop antibodies and HIV-1 gp120.

22 s has been reported to target the glycans on gp120--a glycoprotein found on the surface of the virus

23 ining LDV/I, and the precise determinants of gp120-alpha4beta7 binding are not fully defined.

24 ange chromatography abrogated V2-independent gp120-alpha4beta7 binding.

25 ipeptide motif LDV/I, are thought to mediate gp120-alpha4beta7 binding.

26 tly contradictory observations regarding the gp120-alpha4beta7 interaction and offer new insights int

27 ombinant human fibronectin fragment mediated gp120-alpha4beta7 interactions similarly to CHO cell fib

28 l finding that fibronectins mediate indirect gp120-alpha4beta7 interactions.

29 HIV gp120 also increased TNFalpha, TNFRI, mitochondrial supe

30 LVAC-simian immunodeficiency virus (SIV) and gp120 alum (ALVAC-SIV + gp120) equivalent vaccine, but n

31 s Pasteur's canarypox vector (ALVAC)-HIV and gp120 alum decreased the risk of HIV acquisition in the

32 ant ALVAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SI

33 -molecule CD4-mimetic compounds (CD4mc) bind gp120 and act as competitive inhibitors of gp120-CD4 eng

34 ix proteins can mediate interactions between gp120 and alpha4beta7 This suggests that the extracellul

35 ed to be indispensable for proper folding of gp120 and for viral infectivity.

36 B cells carrying cognate VRC01 receptors by gp120 and gp140 nanoparticles.

37 w that W69, located at the interface between gp120 and gp41 in the PGT151-bound trimer, plays a criti

38 ntry by inhibiting conformational changes in gp120 and gp41 subunits of Env required for entry.

39 Interactions between the gp120 and gp41 subunits of the human immunodeficiency vi

40 sting of a trimer of heterodimers containing gp120 and gp41 subunits that mediates virus entry and is

41 Next, we replace the cleavage site between gp120 and gp41 with various linkers in the context of an

42 imers but includes a covalent linker between gp120 and gp41, an engineered 201-433 disulfide bond, an

43 nd its surface envelope glycoproteins (Env), gp120 and gp41, have evolved immune evasion strategies t

44 monoclonal antibodies (MAbs) that bind HIV-1 gp120 and its mutations under various conditions.

45 Thus, both gp120 and MVAgp140 can augment potential protection of a

46 JM4 binds gp120 and neutralizes HIV-1 strains from subtypes A, B,

47 JM2 binds the CD4-binding site of gp120 and neutralizes HIV-1 strains from subtypes B, C,

48 o, NLRP3-deficient mice immunized with HIV-1 gp120 and QS-21 showed significantly higher levels of Th

49 1 region contributes to the association with gp120 and regulates Env transitions from the unliganded

50 h CD4-induced changes in the conformation of gp120 and the antibody binding site.

51 protection of a DNA/MVA vaccine by enhancing gp120 and V1/V2 antibody responses, whereas potential pr

52 ost immunogens enhanced the breadth of HIV-1 gp120 and V1V2 responses, antibody-dependent cellular cy

53 tor NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Gag-Pol-Nef antigens (NYVAC-C) showed limited

54 of the gp41 fusion peptide and glycan N88 of gp120, and molecular dynamics showed that the N-terminal

55 ed the modeling of glycans on the surface of gp120, and utilized continuum solvent-based loop predict

56 t peak immunogenicity, the magnitudes of the gp120- and V1V2-specific IgG responses were comparable b

57 ilayers that were reconstituted with HIV Env gp120, anti-T cell receptor (anti-TCR) monoclonal antibo

58 ed using beads coated with monomeric gp41 or gp120; anti-V2 MAbs were dominant compared to anti-V3 an

59 mmunogenicity of HIV-1 clade C GagPolNef and gp120 antigens delivered via the poxviral vector NYVAC.

60 in RHPA, which was used to design resurfaced gp120 antigens for single-B-cell sorting.

61 odel of perineural HIV envelope glycoprotein gp120 application onto the rat sciatic nerve to test the

62 n a neuropathic pain model of perineural HIV gp120 application onto the sciatic nerve, we found that

63 ly conserved residues in the inner domain of gp120 are required for HIV-1 envelope glycoprotein (Env)

64 nt peptide V35-Fluo mimicking the V3 loop of gp120, as the molecular target for fluorescence-quenchin

65 show that the gp41 HR1 region contributes to gp120 association with the unliganded Env trimer.

66 Our results show that 36D5 binds gp120 at the base of the V3 loop and suggest that the an

67 We identify the gp120 beta20-beta21 element as a major regulator of Env

68 fection NAb responses correlated with weaker gp120 binding and lower plasma total IgG titers.

69 ein specific for both the CD4 and coreceptor gp120-binding sites.

70 ein specific for both the CD4 and coreceptor gp120-binding sites.

71 ies demonstrated that HIV-1 envelope protein gp120 binds and signals through alpha4beta7 and that thi

72 go entry-related conformational changes when gp120 binds sequentially to the receptors, CD4 and CCR5,

73 Fusion is achieved after gp120 binds to CD4, the HIV-1 receptor, and a coreceptor

74 d in a preclinical model by a poxvirus prime-gp120 boost strategy and that improvements may be achiev

75 on-NAb could be elicited by a poxvirus prime-gp120 boost strategy in a rabbit model.

76 responses were particularly enhanced by the gp120 boost, whereas the MVAgp140 boost also enhanced re

77 ld be improved by substituting the monomeric gp120 boost, with the full-length single-chain (FLSC) pr

78 egimen received an i.n./i.m. combined C.1086 gp120 boost.

79 Two conformations of gp120 bound with CD4 are revealed, suggesting an intrins

80 y responses, whereas potential protection by gp120, but not MVAgp140 boosts, may be further impacted

81 Interestingly, gp120, but not the MVAgp140 boost, increased peak CD4(+)

82 h reveals large structural rearrangements in gp120, but small changes in gp41, compared with closed E

83 gG responses against a linear epitope in the gp120 C1 region of the HIV-1 envelope glycoprotein.

84 We first demonstrate that both V1V2 and gp120 can be presented in native-like trimeric conformat

85 Knowing the site-specific glycosylation of gp120 can facilitate the rational design of glycopeptide

86 d gp120 and act as competitive inhibitors of gp120-CD4 engagement.

87 of the branched pentamannan core of the HIV1-gp120 complex.

88 Germline bNAb-426c gp120 complexes showed preservation of VRC01-class signa

89 built homology models of the three antibody-gp120 complexes, extended the sampling times for large b

90 ferent binding modes compared to mature bNAb-gp120 complexes.

91 The V3 loop of the gp120 component of the Env trimer contributes to the cor

92 e glycans are among the major targets on the gp120 component of the HIV envelope protein (Env) for br

93 inct sequential steps in CD4i transitions of gp120 conformations, each defined by antibody specificit

94 included a recombinant HIV glycoprotein 120 (gp120) construct fused to a small portion of herpes simp

95 vation of VRC01-class signature residues and gp120 contacts, but detectably different binding modes c

96 ization compared with animals immunized with gp120 core alone.

97 ch, we engineered an immunogen consisting of gp120 core in complex with the prototypic CD4-induced Ab

98 The atomic structures of CD4 complexed with gp120 core molecules (a form of gp120 in which the V1, V

99 Mapping studies using gp120 core protein, single-residue knockout mutants, and

100 Structural studies of HIV-1 gp120 coree W69A/S115W mutant bound to the CD4 peptide m

101 at the unliganded extended monomeric core of gp120 (coree) assumes an intermediate CD4i conformation

102 ns of EVs, in particular of those that carry gp120, decreases viral infection of human lymphoid tissu

103 ion infectivity increases monotonically with gp120 density and no saturation is observed under the ex

104 in cell culture, virion infectivity follows gp120 density as a sigmoidal dependence and reaches an a

105 The resulting gp120 density per virion is then correlated with the inf

106 st systematic glycosylation site analysis of gp120 derived from virions produced by infected T lympho

107 sis whereas sera from rabbits receiving only gp120 did not.

108 Env-specific memory B cells that are mainly gp120 directed.

109 Indeed, a total of 20 gp120-directed monoclonal antibodies (MAbs) isolated fro

110 tly, the covalent coupling not only enhanced gp120-directed responses compared to soluble trimers, it

111 ost immunization strategy was employed using gp120 DNA and various V1V2-scaffold proteins.

112 NYVAC-C-KC vectors and the protein component gp120 elicited high levels of T cell and humoral immune

113 and Igkappa-humanized mice with the AE.A244 gp120 Env.

114 omes) released by HIV-1 infected cells carry gp120 (Env), a viral protein that mediates virus attachm

115 human immunodeficiency virus type 1 (HIV-1) gp120 envelope (Env) correlated with reduced infection r

116 ORTANCE Approximately 50% of the mass of the gp120 envelope glycoprotein of both HIV and SIV is N-lin

117 calculate the binding affinities between the gp120 envelope glycoprotein of HIV-1 and three broadly n

118 Previous reports indicate that some HIV-1 gp120 envelope proteins bind to and signal through alpha

119 -gp120 fusion immunogen that exposes cryptic gp120 epitopes to the immune system.

120 ency virus (SIV) and gp120 alum (ALVAC-SIV + gp120) equivalent vaccine, but not an ALVAC-SIV + gp120

121 nv spikes on a virion, whereas its monomeric gp120 exposes many nonneutralizing or strain-specific ep

122 mpounds engage the CD4-binding pocket on the gp120 exterior Env and induce Env conformations that are

123 rect blockade of the interaction between the gp120 exterior envelope glycoprotein and CD4; (ii) prema

124 V-1) and simian immunodeficiency virus (SIV) gp120 exterior envelope glycoprotein to CD4 triggers con

125 elope glycoproteins (Env), a trimer of three gp120 exterior glycoproteins, and three gp41 transmembra

126 s and SIV-infected rhesus monkeys, including gp120-focused responses and rapid development of autolog

127 FLSC is a CD4-gp120 fusion immunogen that exposes cryptic gp120 epitop

128 Our observations demonstrate that core gp120 glycans are not essential for folding, and hence t

129 ved HIV-1 Env variants that lack all 15 core gp120 glycans, yet retain conformational integrity and m

130 The binding of the HIV-1 gp120 glycoprotein to CD4 triggers conformational change

131 The engagement of the HIV-1 gp120 glycoprotein to the host CD4 protein triggers conf

132 When sequentially immunized with modified gp120 glycoproteins designed to engage VRC01 germline an

133 alysis of a cross-clade panel of recombinant gp120 glycoproteins.

134 sion, these results clarify the role of core gp120 glycosylation and illustrate a general method for

135 ent years, however, it has become clear that gp120 glycosylation can also be included in the targets

136 Over half of the gp120 glycosylation sites on 11 different trimeric Envs

137 Here we explore the patterns of HIV-1 Env gp120 glycosylation, and particularly the enrichment in

138 cytic cells of fluorescent beads coated with gp120, gp41, BG505 SOSIP.664, or BG505 DS-SOSIP.664 comp

139 V-1 envelope (Env) glycoprotein, a trimer of gp120-gp41 heterodimers, relies on conformational flexib

140 ecific and cleavage-dependent epitope at the gp120-gp41 interface of the envelope glycoprotein (Env),

141 ies focused on the V2 and V3 regions and the gp120-gp41 interface, we developed the CZA97 SOSIP.v4.2-

142 he coreceptor mimicking antibody 17b and the gp120-gp41 interface-spanning antibody 8ANC195, that can

143 lycan shield covering the surface of the HIV gp120/gp41 envelope (Env) trimer, and how the glycan shi

144 1 envelope glycoprotein (Env) is a trimer of gp120/gp41 heterodimers that mediates viral entry.

145 The envelope glycoprotein (Env) gp120/gp41 is required for HIV-1 infection of host cells

146 he available three-dimensional structures of gp120/gp41 or their complexes with neutralizing antibodi

147 pe spike [Env; trimeric (gp160)3 cleaved to (gp120/gp41)3] induces membrane fusion, leading to viral

148 e spike [Env; trimeric (gp160)3, cleaved to (gp120/gp41)3] poses challenges for vaccine development.

149 The V1V2 region of HIV-1 gp120 harbors a major vulnerable site targeted by a grou

150 Gp120 has remarkably high levels of N-linked glycosylati

151 d on glycan analysis of recombinant forms of gp120, here we report the first systematic glycosylation

152 In the RV144 gp120 HIV vaccine trial, decreased transmission risk was

153 Certain glycan mutants, mutations in the gp120 hydrophobic core, and mutations in residues involv

154 Plasma mapping with monomeric gp120 identified only 2 out of 9 humans and 2 out of 4 m

155 Thus inclusion of additional gp120 immunogens to a pox-prime/protein boost regimen ca

156 ss bNAbs alone and complexed with 426c-based gp120 immunogens.

157 The AE.A244 gp120 in AIDSVAX B/E also bound to the unmutated ancesto

158 ith bivalent FLSC proteins or with monomeric gp120 in alum.

159 FLSC was superior to monomeric gp120 in directing Abs to the C3 alpha2 helix, the V5 lo

160 titution increased the amount of dissociated gp120 in the cell culture supernatant.

161 bstantially increases the binding of 36D5 to gp120 in the intact Env trimer, consistent with CD4-indu

162 mplexed with gp120 core molecules (a form of gp120 in which the V1, V2, and V3 loops and N and C term

163 ures within the second variable loop (V2) of gp120, including the tripeptide motif LDV/I, are thought

164 Plasma mapping with monomeric gp120 indicated that most bnAbs bind to the envelope tri

165 methylbenzene-1,2-diol} (TIMBD) against HIV1-gp120 induced neuroinflammation in SVG astrocytes.

166 HIV gp120 induced overexpression of pC/EBPbeta in the ipsila

167 tic terminals in cortex and hippocampus from gp120-induced damage.

168 tO2(.-)-pCREB triggers pC/EBPbeta in the HIV gp120-induced neuropathic pain state.

169 Moreover, TIMBD attenuated gp120-induced phosphorylation of cJUN, cFOS, STAT3, p38-

170 TIMBD inhibited gp120-induced RNA and protein expression levels of IL6 a

171 exposure to the HIV-related proteins Tat or gp120 induces TREM-1 expression in macrophages and confe

172 ayers (layer 1, layer 2, and layer 3) in the gp120 inner domain contribute to gp120-trimer associatio

173 CD4-induced conformational changes in the gp120 inner domain involve rearrangements between three

174 work suggests that specific residues of the gp120 inner domain layers have coevolved with H375 in or

175 2), and 474 to 476 (layer 3) of the CRF01_AE gp120 inner domain layers to the consensus residues pres

176 coevolution between the Phe43 cavity and the gp120 inner domain layers.

177 CD4, changes the Env conformation to promote gp120 interaction with the second receptor, CCR5 or CXCR

178 , in which antibody residues in the antibody/gp120 interface were systematically mutated to alanine.

179 The conserved CD4 binding site on gp120 is a major target for HIV-1 vaccine design, but ke

180 The HIV-1 envelope glycoprotein gp120 is heavily glycosylated and bears numerous high ma

181 The interaction between 36D5 and SIV gp120 is similar to the interaction between some broadly

182 The V3 loop in gp120 is such a non-NAb epitope that can effectively eli

183 ation of the envelope (Env) surface subunit, gp120, is a key adaptation of HIV-1; however, the precis

184 hy and viral deep sequencing to describe how gp120 lacking glycans in V5 might have elicited these ea

185 ive to layer 1 of HIV-1 gp120, the SIVmac239 gp120 layer 1 plays a more prominent role in maintaining

186 anti-HIV monoclonal antibodies (MAbs), anti-gp120 MAb 924 or anti-gp41 MAb 7B2.

187 displayed stronger activity than other anti-gp120 MAbs in screening against one of two gp120s and ag

188 igher-magnitude antibody levels than adults (gp120 median FIs of 15,509 [infants] and 2,290 [adults],

189 ts immunized with the alum/MNrgp120 vaccine (gp120 median fluorescence intensities [FIs] in infants =

190 ial of being a novel agent for treating HIV1-gp120-mediated neuroinflammatory diseases.

191 equency of gp41-reactive memory B cells than gp120-memory B cells in adult and neonatal RMs.

192 n important role in neuropathology caused by gp120, METH and NT, which are the major pathogenic facto

193 7 nAChR in up-regulation of Abeta induced by gp120, METH and NT.

194 Here, we hypothesized that Glycoprotein 120 (gp120), methamphetamine (METH) and nicotine (NT) can enh

195 ) equivalent vaccine, but not an ALVAC-SIV + gp120 MF59 vaccine, was efficacious in delaying the onse

196 Molecular modeling indicated that HIV gp120 mimicked the chemokine interaction with CCR5, prov

197 trapping virometry to measure the number of gp120 molecules on individual HIV-1 virions.

198 at acquired the ability to bind to the HIV-1 gp120 monomer when adding 2- to 7-amino acid mutations v

199 of these 30 PG9 chimeras bound to the HIV-1 gp120 monomer, and two were neutralizing.

200 lope trimer (including gp41) rather than the gp120 monomer.

201 y to the native Env trimer and weakly to the gp120 monomer.

202 nding uncleaved pseudotrimer and the matched gp120 monomer.

203 bind to the envelope trimer rather than the gp120 monomer.

204 Env gp140 (native or uncleaved molecules) or gp120 monomeric proteins elicit relatively poor B-cell r

205 by several Env vaccine candidates, including gp120 monomers.

206 ex-immunized rabbits displayed footprints on gp120 more distal from the bridging sheet as compared wi

207 E/E/E/E vaccine to increase the diversity of gp120 motifs in the immunogen to elicit a broader antibo

208 have been employed to study a collection of gp120 mutations and truncations.

209 05-SOSIP.664 Env (but with neither monomeric gp120 nor clade C membrane-proximal external region pept

210 tralization breadth via epitopes on trimeric gp120 not yet reported and confer autologous neutralizat

211 y conserved threonine near the C terminus of gp120 of human immunodeficiency virus (HIV) and simian i

212 he V3 loop monoclonal antibody (MAb) 36D5 to gp120 of the SIV Env trimer.

213 llowed by two i.m. boosts with monomeric SIV gp120 or oligomeric SIV gp140 proteins.

214 protein, a V3 polypeptide derived from HIV-1 gp120, or a simple 9-fluorenylmethyl chloroformate-prote

215 Here we show that the gp120 Phe 43 cavity modulates the propensity of Env to s

216 r tryptophan for serine 375 (S375H/W) in the gp120 Phe 43 cavity, where Phe 43 of CD4 contacts gp120,

217 fering levels of viral control using HIV Env gp120 probes and characterized the functionality of matc

218 vary (CHO) cells used to express recombinant gp120 produced fibronectins and other extracellular matr

219 th NYVAC-C-KC vectors plus the clade C HIV-1 gp120 protein (weeks 12 and 24).

220 The gp120 protein boost elicited earlier and higher peak res

221 ith a novel recombinant vaccinia virus prime-gp120 protein boost regimen generated antibodies that re

222 y protective antibody responses, whereas the gp120 protein boosts also increased CD4(+) T cell respon

223 tudy, we evaluated whether the addition of a gp120 protein in alum or MVA-expressed secreted gp140 (M

224 s by stabilizing a conformation of the virus gp120 protein not recognized by the host cell CD4 recept

225 plore the ability of boosts with recombinant gp120 protein or MVA-expressed gp140 to enhance antibody

226 ed to obtain and purify the full recombinant gp120 protein.

227 of alpha4beta7 binding has been reported in gp120 proteins containing LDV/I, and the precise determi

228 in the DP6-001 trial showed broad binding to gp120 proteins of diverse subtypes both autologous and h

229 to mediate the binding of a diverse panel of gp120 proteins to alpha4beta7 in an in vitro cell bindin

230 The gp120 protomers are rotated and separated in the CD4-bou

231 evious influenza infection, we also obtained gp120-reactive antibodies from non-HIV-infected donors,

232 In support of this, none of the isolated gp120-reactive monoclonal antibodies (MAbs) displayed th

233 umans and 2 out of 4 macaques that contained gp120-reactive neutralizing antibodies, indicating disti

234 Interestingly, none of the intersubtype gp120 recombinants recombined between C1 and gp41 region

235 d in vaccine efficacy, whereas the monomeric gp120 regimen significantly decreased the risk of SIVmac

236 s to V2 correlated, whereas in the monomeric gp120 regimen, V2 Abs in rectal secretions, the site of

237 e loops and the others in the remaining core gp120 region.

238 Phe 43 cavity, where Phe 43 of CD4 contacts gp120, results in the spontaneous sampling of an Env con

239 rystal structure of CAP257-RH1 bound to RHPA gp120 revealed critical interactions with the N276 glyca

240 loop, the inner domain, and the C5 region of gp120, revealed genetic similarity between the human and

241 rent phylogenetic methods, we analyzed viral gp120 sequences obtained from extensive longitudinal sam

242 nv protomers were occupied by the CD4mc, and gp120 shedding from the Env trimer was increased in the

243 nse of rabbits on the V1V2 epitopes of HIV-1 gp120 since such antibodies were associated with reduced

244 use of AGMs to model induction of functional gp120-specific antibodies by HIV vaccine strategies.

245 on could elicit potent and broadly reactive, gp120-specific antibodies with positive neutralization a

246 that vaccine adjuvants differently modulate gp120-specific antibody responses in adults and infants

247 ) T cells were significantly associated with gp120-specific B cell frequencies.

248 V antigen specificities were associated with gp120-specific B cell levels.

249 ite controllers displayed greater amounts of gp120-specific B cells in the resting memory subset, whe

250 Therapy (SMART) trial robustly boosted HIV-1 gp120-specific Fc receptor-binding antibodies and ADCC a

251 This work provides evidence that gp120-specific IgA was capable of modifying ADCC respons

252 progressors, we found that a small subset of gp120-specific interleukin-21 (IL-21)-secreting CXCR5(+)

253 Furthermore, AGM gp120-specific monoclonal antibodies display robust anti

254 The binding of CD4 triggers a range of gp120 structural rearrangements that could present targe

255 es impact both accepted paradigms concerning gp120 structure and the field of HIV immunogen design.

256 Human immunodeficiency virus type 1 (HIV-1), gp120(SU) plays an essential role in virus binding to ta

257 inant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31

258 quired substitutions in the C1 domain of the gp120 subunit (A60E, E64K, and H66R) that rendered these

259 The gp120 subunit of the HIV-1 envelope (Env) protein is hea

260 cell-mediated cytotoxicity activity against gp120 targets (p = 0.026) and with Ab-dependent phagocyt

261 in to CD4 triggers conformational changes in gp120 that allow high-affinity binding to its coreceptor

262 4 protein triggers conformational changes in gp120 that allow its binding to co-receptors and is nece

263 onal transitions possible in HIV-1 monomeric gp120 that are affected by CD4 binding.

264 e-guided design of HIV-1 cyclically permuted gp120 that forms homogeneous, stable trimers, and displa

265 nt monoclonal Abs targeting the V1V2 loop of gp120 that had low or no neutralizing activity.

266 in to CD4 triggers conformational changes in gp120 that promote its interaction with one of the chemo

267 Relative to layer 1 of HIV-1 gp120, the SIVmac239 gp120 layer 1 plays a more prominen

268 In the HIV-1 envelope protein gp120, they overlap with known antigenic sites.

269 dependent on folding of the soluble subunit gp120 to a near-native conformation.

270 required for fibronectin-mediated binding of gp120 to alpha4beta7, nor did V2-specific antibodies blo

271 Binding of gp120 to the receptor, CD4, changes the Env conformation

272 cultures, neuroprotection by IFNbeta against gp120 toxicity is dependent on IFNalpha receptor 1 (IFNA

273 to 3 for HIV-1 and layers 1 and 2 for SIV on gp120 transition to the CD4-bound conformation has been

274 A prime-protein boost regimen with these new gp120 trimer immunogens elicited potent neutralizing ant

275 1 plays a more prominent role in maintaining gp120-trimer association but is minimally involved in pr

276 r 3) in the gp120 inner domain contribute to gp120-trimer association in the unliganded state but als

277 sults suggest that cyclically permuted HIV-1 gp120 trimers represent a viable platform in which furth

278 es from fetuin, glycophorin A, ovalbumin and gp120 tryptic digests were used to build a spectral data

279 However, the version of gp120 used in previous studies was not from human T cell

280 l-characterized closed Env conformation, the gp120 V1V2 loops interact at the apex of the Env trimer.

281 he different structural conformations of the gp120 V1V2 vulnerable site can be designed and that thes

282 Monoclonal antibodies directed against the gp120 V2 and V3 variable regions were isolated from the

283 GDIR(327) peptide stretch at the base of the gp120 V3 loop and its nearby glycans.

284 Among the latter are epitopes in the gp120 V3 region that are highly immunogenic when SOSIP t

285 into the dominant site for tier-1 NAbs, the gp120 V3 region, to block the induction of off-target an

286 e ability of antibodies induced by ALVAC-SIV/gp120 vaccination, given with alum or MF59 adjuvant, to

287 infants with an MF59-adjuvanted recombinant gp120 vaccine induced higher-magnitude, potentially prot

288 (IL)-17, as well as with mucosal IgG to the gp120 variable region 2 (V2) and the expression of 12 ge

289 ity of CCR5 to recognize diverse ligands and gp120 variants.

290 airpins have been revealed when CD4-liganded gp120 was compared to CD4-unliganded trimeric envelope s

291 C/EBPbeta gene promoter regions in rats with gp120 was higher than that in sham rats.

292 ce of antibodies to the V1V2 region of HIV-1 gp120 was responsible for the modest protection observed

293 n D (gD) so that the first 40 amino acids of gp120 were replaced by the signal sequence and the first

294 argeting the viral surface glycoprotein 120 (gp120) were selected, synthesized, and assayed.

295 rged in gp41 (62%) and C1 (25.3%) domains of gp120, which has strong correlation with the similarity

296 n state epitopes in the HIV surface antigen, gp120, while not exposed on free particles, rapidly beco

297 s to maintain the noncovalent association of gp120 with gp41 and to evade the host antibody response

298 with antibodies (Abs) to the V1V2 region of gp120 with high antibody-dependent cellular cytotoxicity

299 this Thr was critical for the association of gp120 with the virion and that amino acid substitution i

300 affinities of the new aptamers for the HIV-1 gp120 without the need to obtain and purify the full rec